170 related articles for article (PubMed ID: 20711172)
1. Fibroblast-activation protein: a single marker that confidently differentiates morpheaform/infiltrative basal cell carcinoma from desmoplastic trichoepithelioma.
Abbas O; Richards JE; Mahalingam M
Mod Pathol; 2010 Nov; 23(11):1535-43. PubMed ID: 20711172
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast-activation protein: valuable marker of cutaneous epithelial malignancy.
El Khoury J; Kurban M; Kibbi AG; Abbas O
Arch Dermatol Res; 2014 May; 306(4):359-65. PubMed ID: 24595644
[TBL] [Abstract][Full Text] [Related]
3. Microcystic adnexal carcinoma: an immunohistochemical reappraisal.
Hoang MP; Dresser KA; Kapur P; High WA; Mahalingam M
Mod Pathol; 2008 Feb; 21(2):178-85. PubMed ID: 18065959
[TBL] [Abstract][Full Text] [Related]
4. Expression of p75 neurotrophin receptor in desmoplastic trichoepithelioma, infiltrative basal cell carcinoma, and microcystic adnexal carcinoma.
Jedrych J; McNiff JM
Am J Dermatopathol; 2013 May; 35(3):308-15. PubMed ID: 23598854
[TBL] [Abstract][Full Text] [Related]
5. The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers.
Sellheyer K; Nelson P; Kutzner H; Patel RM
J Cutan Pathol; 2013 Apr; 40(4):363-70. PubMed ID: 23398472
[TBL] [Abstract][Full Text] [Related]
6. Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery.
Merritt BG; Snow SN; Longley BJ
Cutis; 2010 May; 85(5):254-8. PubMed ID: 20540416
[TBL] [Abstract][Full Text] [Related]
7. Does Immunohistochemistry Add to Morphology in Differentiating Trichoepithelioma, Desmoplastic Trichoepithelioma, Morpheaform Basal Cell Carcinoma, and Microcystic Adnexal Carcinoma?
Mohanty SK; Sardana R; McFall M; Pradhan D; Usmani A; Jha S; Mishra SK; Sampat NY; Lobo A; Wu JM; Balzer BL; Frishberg DP
Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):273-277. PubMed ID: 35384877
[TBL] [Abstract][Full Text] [Related]
8. Morpheaform Basal Cell Carcinomas With Areas of Predominantly Single-Cell Pattern of Infiltration: Diagnostic Utility of p63 and Cytokeratin.
East E; Fullen DR; Arps D; Patel RM; Palanisamy N; Carskadon S; Harms PW
Am J Dermatopathol; 2016 Oct; 38(10):744-50. PubMed ID: 27043336
[TBL] [Abstract][Full Text] [Related]
9. PHLDA1 (TDAG51) is a follicular stem cell marker and differentiates between morphoeic basal cell carcinoma and desmoplastic trichoepithelioma.
Sellheyer K; Krahl D
Br J Dermatol; 2011 Jan; 164(1):141-7. PubMed ID: 20846311
[TBL] [Abstract][Full Text] [Related]
10. Panel vs. single marker for discriminating desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma.
Vollmer RT
J Cutan Pathol; 2009 Feb; 36(2):283; author reply 284. PubMed ID: 19208081
[No Abstract] [Full Text] [Related]
11. Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma?
Katona TM; Perkins SM; Billings SD
J Cutan Pathol; 2008 Feb; 35(2):174-9. PubMed ID: 18190441
[TBL] [Abstract][Full Text] [Related]
12. Desmoplastic Trichoepithelioma: An Uncommon but Diagnostically Problematic Benign Adnexal Tumor.
Bartoš V
Acta Dermatovenerol Croat; 2019 Dec; 27(4):282-284. PubMed ID: 31969246
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of immunohistochemistry in distinguishing trichoepithelioma and basal cell carcinoma: evaluation using tissue microarray samples.
Tebcherani AJ; de Andrade HF; Sotto MN
Mod Pathol; 2012 Oct; 25(10):1345-53. PubMed ID: 22684216
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of cytokeratin 17 immunostaining in morpheaform basal cell carcinoma and for facilitating the detection of tumor cells at the surgical margins.
Anderson-Dockter H; Clark T; Iwamoto S; Lu M; Fiore D; Falanga JK; Falanga V
Dermatol Surg; 2012 Aug; 38(8):1357-66. PubMed ID: 22691048
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma.
López JI; Errarte P; Erramuzpe A; Guarch R; Cortés JM; Angulo JC; Pulido R; Irazusta J; Llarena R; Larrinaga G
Hum Pathol; 2016 Aug; 54():100-5. PubMed ID: 27063470
[TBL] [Abstract][Full Text] [Related]
16. Infiltrative pattern of invasion is independently associated with shorter survival and desmoplastic stroma markers FAP and THBS2 in mucinous ovarian carcinoma.
Köbel M; Kang EY; Lee S; Terzic T; Karnezis AN; Ghatage P; Woo L; Lee CH; Meagher NS; Ramus SJ; Gorringe KL
Histopathology; 2024 Jun; 84(7):1095-1110. PubMed ID: 38155475
[TBL] [Abstract][Full Text] [Related]
17. Stromelysin-3: a potent marker for histopathologic differentiation between desmoplastic trichoepithelioma and morphealike basal cell carcinoma.
Thewes M; Worret WI; Engst R; Ring J
Am J Dermatopathol; 1998 Apr; 20(2):140-2. PubMed ID: 9557781
[TBL] [Abstract][Full Text] [Related]
18. Follicular stem cell marker PHLDA1 (TDAG51) is superior to cytokeratin-20 in differentiating between trichoepithelioma and basal cell carcinoma in small biopsy specimens.
Sellheyer K; Nelson P
J Cutan Pathol; 2011 Jul; 38(7):542-50. PubMed ID: 21352265
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic accuracy of immunohistochemical markers in differentiation between basal cell carcinoma and trichoepithelioma in small biopsy specimens.
Mostafa NA; Assaf M; Elhakim S; Abdel-Halim MRE; El-Nabarawy E; Gharib K
J Cutan Pathol; 2018 Nov; 45(11):807-816. PubMed ID: 29917261
[TBL] [Abstract][Full Text] [Related]
20. Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma.
Hua X; Yu L; Huang X; Liao Z; Xian Q
Diagn Pathol; 2011 Nov; 6():111. PubMed ID: 22067528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
